Conclusion The understanding and utilizing GLP-1 receptor agonists (GLP-1 RAs) underscore their transformative impact on managing type 2 diabetes mellitus (T2DM), obesity, and related cardiometabolic conditions
Compounded GLP-1 Regulatory Status According to FDA statements, legal challenges related to the resolution of the semaglutide shortage are ongoing
In PD, GLP-1RAs prevented the progression of loss of nigrostriatal dopaminergic cells, restored dopamine synthesis, showed anti-inflammatory activity, and improved motor functions [45]
So far, oral GLP-1 therapies have been developed to reduce patient reliance on injections
Key Products: Orforglipron (Foundayo), is first oral GLP-1 receptor agonist developed by the company that can be taken at any time of day
Concurrently, GLP-1 also reduces fat build-up in the liver by activating AMPK, which then inhibits fatty acid synthesis while promoting the breakdown of fatty acids (beta-oxidation), leading to less lipid droplet accumulation in hepatocytes